ImmunoCellular's plan of compliance accepted by NYSE
ImmunoCellular announced that the NYSE has accepted the company's plan to regain compliance with the exchange's continued listing standards. The company was previously notified that it was not in compliance with the stockholders' equity continued listing standard which requires stockholders' equity of $6.0M or more if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The company has been granted until December 23, 2018, subject to periodic review by the NYSE MKT for compliance with the initiatives set forth in the plan, to regain compliance. If the company is not in compliance with the continued listing standards by December 23, 2018, or if it does not make progress consistent with the plan during the plan period, the NYSE MKT staff may initiate delisting proceedings as appropriate. The notice has no immediate impact on the listing of the company's common stock, which will continue to trade on the NYSE MKT exchange under the symbol "IMUC," with the added designation of ".BC" to indicate that the company is not in compliance with listing standards.